A VL increase was detected in all individuals during all STI. However, dynamics of VL rebound changed when the first STI was compared with the fifth. The mean doubling time of VL rebound increased from the first to the last STI [from 2.08 days (SE, 0.38) to 6.2 days (SE, 2.8) (P < 0.05) in the HU group and from 3.3 days (SE, 0.65) to 5.6 days (SE, 1.6) in the HAART group (P < 0.05)] without significant differences between the two groups. There were also no differences in VL rebound at week 2 off therapy when comparing the HU group (mean VL 3.1, 3.5, 3.5 log10 copies/ml during first, second and third STI, respectively) and the HAART group (mean VL 3.7, 3.4, 3.2 log10 copies/ml during first, second and third STI, respectively) (Fig. 2). Conversely, when HU was continued during the period of discontinuation of the other drugs in the fourth and fifth STI, the VL rebound at week 2 off therapy in the HU group was 2.2 and 2.2 log10 copies/ml, respectively (that is, 1 log10 copies/ml lower than during the previous STI periods in the same group), whereas the VL rebound did not change in the HAART group (mean VL 3.2 and 3.1 log10 copies/ml during the fourth and fifth STI, respectively) (Fig. 2).
After the fifth interruption of therapy, the peak of VL rebound was lower in the group maintaining treatment with HU. In this group, a peak VL >5000 copies/ml was observed in only two out of nine compared with eight out of ten patients in the HAART group (P = 0.0185). More importantly, VL remained < 5000 copies/ml in eight out of nine patients in HU group and in four out of ten patients in HAART group after a median of 48 weeks of follow-up after the fifth interruption of therapy (P = 0.039) (Fig. 3). The mean difference between baseline VL before any therapy and the set-point determined by the average of the two last stable measurements (with a difference of less than 0.3 log10 copies/ml) separated by at least 1 month after 24 weeks off therapy during the fifth STI was −1.4 and −0.6 log10 copies/ml in the HU and HAART groups, respectively.
NA was analyzed in 15 individuals who had available serum at baseline before any antiretroviral therapy (seven from the HU group and eight from HAART group). By STI cycle 5, there was a significant increase in the HIV45-specific NA from baseline (P = 0.003) but no increase in HIV40-specific NA. No significant differences were observed between the HAART and HU groups in NA at any time-point. There were no differences in the NA titers at any time-point between responder and non-responder patients.
At baseline, only 7 out of 19 patients showed a moderate to strong CTL response. Both the magnitude and the breadth of the total CTL response progressively improved during STI. The median total CTL response at baseline was 570 SFC/106 PBMC and during STI cycles 1–5 was 698, 582, 1080, 1429 and 2814 SFC/106 PBMC, respectively (P = 0.0001). The breadth of CTL response increased from a median of 3 peptides (range, 0–8) at baseline to 6 peptides (range, 4–16) at STI cycle 5. A weak LPR to HIV-1 p24 protein was detected at baseline in 3 out of 19 patients and after STI cycle 5 in 14 out of 19 patients (P = 0.0003). No significant differences were observed between the HAART and HU groups in CTL and LPR at any time-point. There was a trend for higher CTL and LPR levels in responder patients (P = 0.10 for both) measured at the moment that VL reached the set-point after the fifth discontinuation of antiretroviral therapy. However, three out of eight responder patients in the HU group did not show CTL response or LPR. Conversely, three out of six non-responder patients in the HAART group showed strong CTL and LPR responses. These increases in individual patients were analysed to see if they correlated with greater lengthening of the doubling time of VL rebound from the first to the last STI. The increase in CTL responses was not correlated with the lengthening of the doubling time of VL rebound (r = −0.11; P = 0.68); however the increase in LPR was strongly correlated with lengthening of the doubling time of VL rebound (r = 0.73; P = 0.003). Moreover, the LPR at the moment that VL reached the set-point after the fifth discontinuation of antiretroviral therapy was also strongly correlated with lengthening of the doubling time of VL rebound (r = 0.95; P = 0.0001).
Safety and immune system changes
No patients had to discontinue HAART or HU because of side-effects. VL fell to undetectable levels after reinitiating therapy in all patients at all cycles (Fig. 2). Seven patients had to change therapy because of side-effects (all of them during the period before STI), mostly nephrolithiasis and gastrointestinal complaints (Table 2). In six out of seven patients who changed triple therapy because of side-effects, indinavir was replaced by nelfinavir, and in one case (polyneuropathy) didanosine was changed to lamivudine. Mean fasting cholesterol, triglycerides and glucose levels did not change significantly after 1 year of follow-up. Triglycerides increased to a pathological level in three patients. In two of these, levels went back to normal after discontinuation of HAART. There were four patients with clinical lipodystrophy. None of the patients in whom HU was maintained reported any side-effects during the period off HAART. The proportion of patients with side-effects did not differ between the HU and HAART groups.
From the day of randomization to the day of STI initiation, the absolute number and percentage of CD4 T cells did not change significantly in either the HAART group or the HU group (Fig. 4). The mean CD4 T cells at day 0 before STI in the HAART and HU groups was 957 × 106 cells/l (SE, 69) and 1001 × 106 cells/l (SE, 155), respectively. The mean percentage CD4 T cells at day 0 before STI was 48% (SE, 3) and 40 (4) in the HAART and HU groups, respectively. Non-significant falls in CD4 T cell count were observed from the day of initiation of STI to the day before the fifth STI [mean from 957 × 106 cells/l (SE, 69) to 849 × 106 cells/l (SE, 83) (P = 0.37) in the HAART group and from 1001 × 106 cells/l (SE, 155) to 883 × 106 cells/l (SE, 183) (P = 0.38) in the HU group]. Significant falls in CD4 T cell percentage were observed from the day of initiation of STI to the day before the fifth STI [mean from 48% (SE, 3) to 36% (SE, 2) in the HAART group (P = 0.01) and from 40% (SE, 4) to 34% (SE, 3) in the HU group (P = 0.05)]. Neither absolute numbers nor percentages changed significantly during the follow-up of the fifth STI in both groups. CD4 T lymphocytes did not fall below baseline (500 × 106 cells/l) in any patient at any time.
Current treatment guidelines for HIV infection recommend a relatively late initiation of HAART [26,27] because of adherence problems to a sometimes very complex therapy , the unlikely possibility of eradication of HIV-1 with HAART alone, [25,29–31] and the risk of drug-related side-effects, including serious metabolic abnormalities and apparently irreversible fat redistribution syndromes [32–34]. Moreover, it has not been demonstrated that an earlier initiation of therapy (i.e., at a CD4 T cell count above 350–500 × 106 cells/l) can offer any advantage with regard to further immunological improvement, avoiding development of resistance, control of viral replication, reduction of clinical events or death when compared with starting HAART at a later stage [35,36].
However, these guidelines raise a number of questions that are yet unsolved. First, what should be recommended to those patients who started therapy when their CD4 T cell counts were above the current recommendation or to those patients whose CD4 T cell counts increased and stabilized even for years above a high level (i.e., 500 × 106 cells/l) after initiating HAART? Second, not treating patients in earlier stages of HIV-1 infection means that they will await immune system deterioration without any intervention. It would be helpful to implement strategies with less side-effects than the current ‘HAART for life’ to avoid the natural evolution of the disease in patients with high CD4 T cell counts . Lastly, some patients who have not been treated until later stages of the disease will have a high level of VL, which could increase the risk of transmission and cause a public health problem. Alternative strategies gaining more experimental validation are immune-based therapies aimed at controlling HIV-1 replication [38,39]. It has been hypothesized that cyclic interruptions of antiretroviral therapy may boost HIV-1-specific immune responses, reset VL and be considered a modality of immune-based therapy for HIV-1 infection, at least when initiated immediately after acute infection [4,6]. These immune-specific responses seem to be weaker, however, when STI is performed during chronic HIV infection. Moreover, there is contradictory evidence on the possibility of the association of these immune responses with the reset of the VL set-point, occurring in a low proportion of patients (approximately 20% of patients with chronic HIV infection) [8–12].
The data of the present randomized study shows that the maintenance of a single cytostatic drug (namely HU) during the discontinuation of antiretroviral drugs may significantly increase the percentage of patients able to achieve control of viral replication after five cycles of STI and a prolonged period off HAART (median 48 weeks). How can the results be explained? It did not seem that HU had any distinct effect on HIV-specific immune responses. HU might have acted in two other ways: by inhibiting the initial wave of HIV rebound originating from reservoirs such as quiescent lymphocytes, macrophages, or dendritic cells, in which the drug has been shown to be an effective monotherapy [15,16]; or by limiting the subsequent wave of viral replication among activated T lymphocytes by virtue of its cytostatic effects, as suggested by several mathematical models and by a randomized, controlled trial (for a review, see ). The fact that the final set-point and not the initial doubling time was affected by HU strongly favors the latter hypothesis. Moreover, rebound at 2 weeks was similar in both groups when both HU and HAART were discontinued during the first, second and third STI while it was much lower in the HU group when HU was maintained (in cycles 4 and 5). This further supports the hypothesis that HU controls viral replication by virtue of its cytostatic effect on CD4 T lymphocytes. It is important to note that the cytostatic action of HU had no deleterious effects on HIV-1-specific neutralizing antibodies, T-helper or CTL responses. A question that is not answered with this study is whether the same effect on viral replication could be observed if HU were added to a regimen just prior to interruption and then kept on while the antiretroviral drugs were discontinued.
These data also confirm that HIV-1-specific cellular immune responses can be augmented following cycles of therapy interruption in chronic HIV infection, consistent with previous findings [1,2,6,9]. Subjects who had no detectable responses at baseline or after the first STI progressively generated HIV-1-specific neutralizing antibodies and cellular immune responses with repeated cycles of STI. This correlated with a progressive increase in doubling time of VL rebound, however, not with a lowering in VL set-point. It is plausible that the transient, incomplete recovery of HIV-specific immune responses induced by STI in our patients, and, in general, in chronic HIV infection , is sufficient to limit the initial spread of HIV during rebound (doubling time), but it becomes subsequently overwhelmed by the virus without affecting the final set-point.
There are some safety concerns related to STI protocols. One potential problem is the development of drug resistance . In all our patients, VL dropped to undetectable levels when the same treatment was reintroduced. The most serious safety concern associated with STI in our study was a significant fall in the CD4 T cell percentage (but not absolute number) at week 40 (before the fifth and last STI). However, CD4 T cells never fell below the baseline levels (that is, before any antiretroviral therapy). Consequently, this strategy may be considered exclusively in a selected HIV-1-infected population under strict medical supervision, with an objective different from that of ‘drug holidays’ in patients with very advanced disease .
These data represent the first demonstration that control of HIV might be induced during chronic infection by adding a cytostatic drug to STI, thus overcoming one limitation of STI in this patient population. The results may indicate a novel approach, to be tested and confirmed, for the treatment of selected populations of HIV-1-infected patients, such as those who started HAART with a high level of CD4 T cells and now have to continue HAART for many years to come, or patients with high CD4 T cells and a high level of VL who could reset their set-point VL to a lower value and delay the necessity of starting continuous HAART. The combination of STI and cytostatic drugs in HIV-1 infection should proceed with caution until the impact and long-term safety has been further investigated in larger clinical trials.
We thank Julianna Lisziewicz, Elisa de Lazzari, Sebastian Bonhoeffer, and Douglas F Nixon for comments about the manuscript, Claudia Pastori for technical help with the NA assays and Sylva Petrocchi and Al Ruel for editorial assistance. We are indebted to all the participants of the study, laboratory technicians (M. J. Maleno, A. Capón, M. García, and A. García) and to Bristol-Myers-Squibb for supplying the hydroxyurea.
Sponsorship: This study was supported in part by grants FIPSE 3118/00*, FIPSE 3074/99*, SAF 98/0021, FIS 99/0289, FIS 01/1595, SAF 01/2591, FIPSE 36259/01, NIH R01 AI44595, F31 GM20068-01 and ISS/1999 40C52. (FIPSE is a non-profit foundation including the Spanish Ministry of Health, Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers-Squibb, GlaxoSmithKline, Merck Sharp and Dohme and Roche.) Montserrat Plana received a grant by SEIMC (Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica). Gabriel Ortiz is a student in the Tri-Institutional MD–PhD Program supported by the NIH Medical Scientist Training Program Grant GM 0773. Bristol-Myers-Squibb supplied the hydroxyurea.
1.Haslett PA, Nixon DF, Shen Z, Larsson M, Cox W, Manandhar R, et al.Strong human immunodeficiency virus-specific CD4+ T cell responses in a cohort of chronically infected patients are associated withinterruptions in anti-HIV chemotherapy.J Infect Dis
2.Binley J, Schiller D, Ortiz GM, Nixon DF, Markowitz M, Moore JP. The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy.J Infect Dis
3.Lori F, Lewis M, Xu J, Varga G, Zinn D, Crabbs C, et al.Control of SIV rebound through structured treatment interruptions during early infection.Science
4.Lisziewicz J, Rosenberg E, Lieberman J, Jessen H, Lopalco L, Siliciano R, et al.Control of HIV despite the discontinuation of antiretroviral therapy [letter].N Engl J Med
5.Lori F, Maserati R, Foli A, Seminari E, Timpone J, Lisziewicz J. Structured treatment interruptions to control HIV-1 infection.Lancet
6.Rosenberg ES, Altfeld M, Poon S, Phillips M, Wilkes B, Eldridge R, et al.Immune control of HIV-1 after early treatment of acute infection.Nature
7.Ortiz GM, Hu J, Goldwitz J, Chandwani R, Larsson M, Bhardwaj N, et al.Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8 T-cell responses in subjects treated early after infection.J Virol
8.Fagard, C, Lebraz, M, Gunthard, H, Tortajada, C, García, F, et al.SSITT: a prospective trial of strategic treatment interruptions in 128 patients.Eighth Conference on Retroviruses and Opportunistic Infections.
Chicago, February 2001 [abstract 357].
9.García F, Plana M, Ortiz GM, Bonhoeffer S, Soriano A, Vidal C, et al.The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection.AIDS
10.Ruiz L, Carcelain G, Martinez-Picado J, Frost SD, Marcia S, Paredes R, et al.HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection.AIDS
11.Carcelain G, Tubiana R, Samri A, Calvez V, Delaugerre C, Agut H, et al.Transient mobilization of human immunodeciency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection.J Virol
12.Ortiz GM, Wellons M, Brancato J, Vo H, Zinn R, Clarkson D, et al.Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.Proc Natl Acad Sci USA
13.Biron F, Lucht F, Peyramond D. Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals.J Acquir Immune Defic Syndr Hum Retroviruses
14.Foli A, Maserati R, Minoli L, Wainberg MA, Gallo RC, Lisziewicz J, et al.Therapeutic advantage of hydroxyurea and didanosine combination therapy in patients previously treated with zidovudine.AIDS
15.Cao W, Cara A, Gallo RC, Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication.Proc Natl Acad Sci USA
16.Lori F, Malykh A, Cara A, Sun D, Weinstein JN, Lisziewic J, et al.Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication.Science
17.Piccinini, G, Foli, A., Comolli, G, Lisziewicz, J, Lori F. Complementary antiviral efficacy of hydroxyurea and protease inhibitors in human immunodeficiency virus-infected dendritic cells and lymphocytes.J Virol
18.Maurer B, Siebert M, Bassukas I. An in vivo study on the synchronizing effect of hydroxiurea.Exp Cell Res
19.Lori F. Hydroxyurea and HIV: 5 years later-from antiviral to immuno-modulating effects.AIDS
20.García F, Plana M, Vidal C, Cruceta A, O'Brien WA, Pantaleo G, et al.Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.AIDS
21.García F, Alonso M, Romeu J, Knobel H, Arrizabalaga J, Podzamczer D, et al.Comparison of immunological restoration and virological response in plasma, tonsillar tissue and cerebrospinal fluid in HIV-1 infected patients treated with double versus triple antiretroviral therapy in very early stages. The Spanish Earth-2 Study.J Acquir Immune Defic Syndr
22.Schockmel G, Yerly S, Perrin L. Detection of low HIV-1 RNA levels in plasma.J Acquir Immune Defic Syndr Hum Retroviruses
23.Lopalco L, Barassi C, Pastori C, Longhi R, Burastero SE, Tambussi G, et al.CCR5-reactive antibodies in seronegative partners of HIV seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 in vitro.J Immunol
24.Pesenti E, Pastore C, Lillo F, Siccardi AG, Vercelli D, Lopalco L. Role of CD4 and CCR5 levels in the susceptibility of primary macrophages to infection by CCR5-dependent HIV type 1 isolates.AIDS Res Hum Retroviruses
25.Ho DD, Neumann AU, Perelson AS, Chen WVA, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytres in HIV-1 infection.Nature
26.British HIV Association (BHIVA). Guidelines for the Treatment of HIV-Infected Adults with Antiretroviral Therapy
. July 2001. http://www
aidsmap com/about/bhiva/guidelines pdf
27.National Institutes of Health. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents (NIH).
February 2002. http://hivatis
28.Knobel H, Carmona A, Grau S, Pedro-Botet J, Diez A. Adherence and effectiveness of highly active antiretroviral therapy [letter].Arch Intern Med
29.Wei X, Ghosh S, Taylor M, Johson VA, Emini EA, Deutsh P, et al.Viral dynamics in human immunodeficiency virus type 1 infection.Nature
30.Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span and viral generation time.Science
31.Finzi D, Blankson J, Siliciano JD. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.Nat Med
32.Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidemia and diabetes mellitus: a cohort study.Lancet
33.Martinez E, Gatell J. Metabolic abnormalities and use of HIV-1 protease inhibitors [letter].Lancet
34.Martinez E, Mocroft A, García-Viejo M, Pérez-Cuevas J, Blanco J, Mallolas J, et al.A prospective cohort study on the risk for lipodystrophy in HIV-1 infected patients treated with protease inhibitor-containing regimens.Lancet
35.Phillips AN, Staszewki S, Weber R, Kirk O, Francioli P, Miller V, et al.HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.J Am Med Assoc
36.Hogg RS, YIP B, Chan K, Wood E, Craib KJP, O'Shaughnessy MV, et al.Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.J Am Med Assoc
37.Dybul M, Chun TW, Yoder C, Hidalgo B, Belson M, Hertogs K, et al.Short-cycle structured treatment of chronic HIV infection with higly active antiretroviral therapy: effects on virologic, immunologic and toxicity paramenters.Proc Natl Acad Sci USA
38.Sereti I, Lane C. Immunopathogenesis of human immunodeficiency virus: implications for immune-based therapies.Clin Infect Dis
39.Cohen D, Walker BD. Human immunodeficiency virus pathogenesis and prospects form immune control in patients with established infection.Clin Infect Dis
40.Richman DD. The challenge of immune control of immunodeficiency virus.J Clin Invest
41.Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour J, et al.Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.N Engl J Med
Keywords:© 2003 Lippincott Williams & Wilkins, Inc.
structured therapy interruption; HIV-1 infection; hydroxyurea